Explore the Agenda
7:00 am Check In & Light Breakfast
7:50 am Chair’s Opening Remarks
Optimizing Proteomics Workflows With High Throughput Methodologies Including Mass
Spectrometry & Beyond to Enable Protein Analysis at Scale
8:00 am Developing Highly Sensitive, High Throughput Methodologies to Perform Time & Cost-Effective Proteomics Analysis to Support Drug Discovery at Scale
- Achieving proteomics workflows at an unprecedented scale with optimized analysis methodologies
- Balancing coverage, throughput, and sensitivity of proteomic platforms to accurately analyze the proteome, including low-abundance proteins
- Exploring data showing how proteomics can transform drug discovery and unlock otherwise undruggable targets
8:30 am Facilitating Efficient Proteomic Analysis With High Throughput Mass Spectrometry Capabilities to Power Drug Discovery Pipelines
- Evaluating automation, mass spectrometry instruments, and selecting appropriate technologies based on project demands, cost, and internal capabilities
- Achieving optimal levels of throughput and sensitivity to meet project demands
- Reviewing data showing the unique benefit of implementing high-throughput mass spectrometry-based proteomics for degrader profiling in the early stage of drug discovery
9:00 am Optimizing Scalable Proteomics Techniques for Efficient Target Deconvolution & Small Molecule Drug Discovery
- Developing workflows to enable high throughput chemoproteomic analysis with enhanced efficiency
- Strategically optimizing sensitivity, coverage, and throughput to detect a full range of proteins, including those in low abundance
- Evidence to show how proteomics accelerates drug discovery and unlocks previously inaccessible targets
9:30 am Session Reserved for Syncell
10:00 am Morning Break & Speed Networking
Network with your peers on this exclusive session to exchange your ideas and generating meaningful industry connections and collaborations with other leaders in the proteomics field
Leveraging the Power of Immunopeptidomics to Guide the Discovery of Efficacious, Safe
Therapies
11:00 am Quantitative Immunopeptidomics Drives Target Discovery & Rational Antibody Design for T Cell Engagers
- Exploring how high-sensitivity, targeted immunopeptidomics enable direct detection and detailed characterization of drug-modified (haptenated) peptide–MHC complexes, informing the rational design of bispecific T cell engagers with cross-HLA reactivity
- Outlining how the quantitative profiling of amplified MHC-I targets defines the therapeutic window and guides engineering of T cell engagers against canonical, mutation-agnostic epitopes such as pan-KRAS amplification
- Integrating immunoproteomics-driven target validation with antibody engineering to accelerate the development of next-generation T cell engagers, exemplified by programs targeting mutant KRAS, KRAS amplification, and p53 mutants
11:30 am A Multi-Omics Platform for Comprehensive pHLA Target Discovery & Validation
- Leveraging immunopeptidomics to profile and measure cell surface proteins that guide therapeutic decision-making
- Harnessing immunopeptidomics insights to discover and confirm new peptide targets for antibody therapies
- Tackling issues of low-abundance targets and assay sensitivity through cutting-edge technologies and instruments
12:00 pm Combining Mass Spectrometry & Alternative Proteomics Platforms to Achieve Optimized Coverage & Throughput for Rapid, Comprehensive Proteomic Analysis
- Demonstrating the benefits of utilizing mass spectrometry and other proteomics platforms, drawing on the advantages of multiple technologies to unlock greater insights
- Allocating budgets and managing resources effectively to strategically leverage multiple proteomics platforms to achieve maximum insights from patient data
- Deep diving into data from a drug discovery breakthrough made possible with proteomics
12:30 pm Increasing Understanding of the Immune System With Immunopeptidomics to Guide the Discovery of Efficacious, Safe Immunotherapies
- Applying immunopeptidomics to detect and quantify cell surface proteins to inform therapeutic strategy
- Using immunopeptidomics data to identify and validate novel peptide targets for immunotherapies, vaccines and beyond
- Overcoming challenges in low abundance and limited assay sensitivity with advanced technology and AI capabilities
1:00 pm Lunch Break & Networking
Exploring Innovative Methodologies Across Spatial Proteomics & Single Cell Analysis to
Unlock Novel Biomedical Insights
2:00 pm Protein Nanoscale Organization: Unlocking Surfaceomes to Power Next-Generation Therapeutics
- Introducing DISCOtech: DISCO's proprietary surfaceome proteomics platform and workflow to systematically map nanoscale organizations on the cell-surface proteins across tumor types
- Demonstrating how DISCOtech reveals tumor-specific vulnerabilities inaccessible through traditional genomics or transcriptomics
- Showcasing the translation from surfaceome discoveries to target candidates into differentiated antibody-based therapeutics with enhanced efficacy and safety profiles
2:30 pm Understanding Heterogeneity With Single-Cell Proteomics to Elucidate Drivers of Disease, Resistance & Immune Response
- Utilizing single-cell technology to understand cell-to-cell protein variability, rare cell populations and functionally significant proteins
- Applying single-cell proteomics to predict therapeutic response, elucidate cell-specific disease mechanisms and inform patient stratificationÂ
3:00 pm Afternoon Break & Poster Session
This is your opportunity to share your work with fellow members of the community, showcasing how your drug discovery breakthroughs were made possible with proteomics.
Strategically Balancing Sensitivity, Coverage & Throughput of Proteomics Tools &
Methodologies to Ascertain a Holistic Understanding of the Proteome
Strategically Balancing Sensitivity, Coverage & Throughput of Proteomics Tools & Methodologies to Ascertain a Holistic Understanding of the Proteome
3:45 pm Proteomics Along the TPD Pipeline – Enabling Lead Optimization Through Clinical Biomarker Development
- Exploring how proteomics is employed throughout the drug discovery process for targeted protein degradation
- Outlining how global proteomics helps guide medicinal chemistry and understand compound effects
- Discovering how targeted MS-based proteomics and alternative platforms can provide essential and exploratory clinical biomarkers
4:15 pm Round Table Discussion: Harmonizing Coverage, Specificity & Throughput to Enable Sensitive, Comprehensive Proteomics Analysis
- Selecting appropriate instruments and methodologies and developing sensitive assays to enable accurate protein detection
- Standardizing analysis pipelines using protocols from academic consortia and biobanks to ensure reproducibility and scalability
- Combining in-house analysis, external capabilities, and AI platforms to quantify the proteome and draw meaningful biomedical conclusions from proteomics data sets
5:00 pm Proteomics in Precision Medicine & Drug Development: From Biomarkers to Companion Diagnostics
- Outlining the unique benefits of adopting proteomics in precision medicine
- Developing better biomarkers using insights generated from proteomics
- Exploring data that shows how proteomics can be used as companion diagnosticsÂ